Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 11, 2026

Synopsys Outlines Vision for Engineering the Future

View original at finance.yahoo.com
Synopsys Outlines Vision for Engineering the Future Announces new design, verification and simulation solutions to re-engineer AI-powered product innovation at Synopsys Converge 2026 Key Highlights Unveiling Synopsys Multiphysics Fusion™ technology — the first in a broader roadmap of EDA solutions that integrate Synops…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • By integrating co-design of software and hardware, electronics and physics, by harnessing digital twins to design, test, and refine products before physical production, and using AI to enhance human capabilities, customers' R&D teams can accelerate time to market of their intelligent systems

    60% confidence

  • Synopsys' silicon-to-systems engineering solutions make them the best partner for engineering the future

    60% confidence

  • The complexity of next-generation intelligent systems requires a completely new engineering approach

    60% confidence

  • By integrating co-design of software and hardware, electronics and physics, by harnessing digital twins to design, test, and refine products before physical production, and using AI to enhance human capabilities, customers' R&D teams can accelerate time to market of their intelligent systems

    60% confidence

  • Synopsys silicon-to-systems engineering solutions make them the best partner for engineering the future

    60% confidence

  • The new silicon-to-systems design paradigm for the era of pervasive intelligence is silicon-powered, AI-enabled, and software-defined

    60% confidence

  • Multiphysics Fusion technology is the first in a broader roadmap of EDA solutions that integrate Synopsys and Ansys technologies for semiconductor design

    60% confidence

  • The L4 orchestrated, multi-agent design and verification workflow powered by AgentEngineer technology is an industry-first

    60% confidence

  • The complexity of next-generation intelligent systems requires a completely new engineering approach

    60% confidence

  • By integrating co-design of software and hardware, electronics and physics, by harnessing digital twins to design, test, and refine products before physical production, and using AI to enhance human capabilities, customers' R&D teams can accelerate time to market of their intelligent systems

    60% confidence

  • Synopsys' silicon-to-systems engineering solutions make them the best partner for engineering the future

    60% confidence

  • The complexity of next-generation intelligent systems requires a completely new engineering approach

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Synopsys Outlines Vision for Engineering the Future — Source | Via News | Finance Via News